Tirofiban hydrochloride

Modify Date: 2024-01-02 09:12:15

Tirofiban hydrochloride structure	Common Name	Tirofiban hydrochloride
	CAS Number	150915-40-5	Molecular Weight	495.073
	Density	N/A	Boiling Point	611.7ºC at 760 mmHg
	Molecular Formula	C₂₂H₃₉ClN₂O₆S	Melting Point	135-137ºC
	MSDS	Chinese USA	Flash Point	323.7ºC
	Symbol	GHS07	Signal Word	Warning

Use of Tirofiban hydrochloride

Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistIC50 value:Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml).

Name	tirofiban hydrochloride
Synonym	More Synonyms

Description	Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistIC50 value:Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml).
Related Catalog	Signaling Pathways >> Cytoskeleton >> Integrin Research Areas >> Cardiovascular Disease
References	[1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. [2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. [3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. [4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. [5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.

Description

Related Catalog

Signaling Pathways >> Cytoskeleton >> Integrin

Research Areas >> Cardiovascular Disease

References

[1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46.

[2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.

[3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.

[4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.

[5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.

Boiling Point	611.7ºC at 760 mmHg
Melting Point	135-137ºC
Molecular Formula	C₂₂H₃₉ClN₂O₆S
Molecular Weight	495.073
Flash Point	323.7ºC
Exact Mass	494.221741
PSA	122.34000
LogP	5.48870
Storage condition	-20°C Freezer
Water Solubility	DMSO: >12mg/mL at warmed to 60°C

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H315-H319-H335
Precautionary Statements	P261-P305 + P351 + P338
Hazard Codes	Xi
Risk Phrases	36/37/38
Safety Phrases	26-37-45
RIDADR	NONH for all modes of transport

Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose.

J. Clin. Lab Anal. 30 , 108-13, (2016)

Activated clotting time (ACT) has been successfully applied during percutaneous coronary intervention (PCI) to monitor the extent of thrombin inhibition and anti-coagulation from unfractionated hepari...

L 700462 MK 383 N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine

N-(butylsulfonyl)- O-[4-(4-piperidinyl)butyl]-L-tyrosine monohydrochloride monohydrate

N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]tyrosine hydrochloride hydrate

N-(Butylsulfonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine hydrochloride hydrate

(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid,hydrate,hydrochloride

Tirofiban hydrochloride

Tirofiban hydrochloride monohydrate

tirofiban hydrochloride anhydrous

Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-, hydrochloride, hydrate (1:1:1)

Tirofiban Hydrochloride Hydrate

Tirofiban (hydrochloride monohydrate)